ライフサイエンスコーパス: T-cell lymphoma

1 inhibitors that are efficacious in cutaneous T cell lymphoma.

2 it is believed to be the cause of peripheral T cell lymphoma.

3 on of immature thymocytes and development of T cell lymphoma.

4 s with peripheral (PTCL) or cutaneous (CTCL) T-cell lymphoma.

5 es that demonstrated preliminary activity in T-cell lymphoma.

6 dy, in 41 pretreated patients with cutaneous T-cell lymphoma.

7 ggressive CD4+ leukemic variant of cutaneous T-cell lymphoma.

8 ymphoma, and four of eight with noncutaneous T-cell lymphoma.

9 drug approved for the treatment of cutaneous T-cell lymphoma.

10 se agents to treat skin cancer and cutaneous T-cell lymphoma.

11 ymphoma, Burkitt's lymphoma, or noncutaneous T-cell lymphoma.

12 pGs have demonstrated efficacy for cutaneous T-cell lymphoma.

13 h, including atopic dermatitis and cutaneous T-cell lymphoma.

14 ncer, lentigo maligna melanoma and cutaneous T-cell lymphoma.

15 AC inhibitors for the treatment of cutaneous T-cell lymphoma.

16 an attractive strategy for the treatment of T-cell lymphoma.

17 es the second most common group of cutaneous T-cell lymphoma.

18 nd management of relapsed angioimmunoblastic T-cell lymphoma.

19 dary suppression of p53 in invasive nasal NK/T-cell lymphoma.

20 cceptable toxicity in refractory or relapsed T-cell lymphoma.

21 n of 2 of 10 cases of enteropathy-associated T-cell lymphoma.

22 lymphoblastic T-cell leukemia and cutaneous T-cell lymphoma.

23 es (MF) is the most common primary cutaneous T-cell lymphoma.

24 ymphoma and large-cell transformed cutaneous T-cell lymphoma.

25 (MF) is the most frequent form of cutaneous T-cell lymphoma.

26 tory Hodgkin's lymphoma and anaplastic large-T-cell lymphoma.

27 sis fungoides, a common variant of cutaneous T-cell lymphoma.

28 activity in large-cell transformed cutaneous T-cell lymphoma.

29 could have a critical role in the biology of T-cell lymphoma.

30 a condensin II subunit (Caph2(nes)) develop T-cell lymphoma.

31 lating agent MNU, which predominantly caused T cell lymphomas.

32 ukemia (T-ALL) and in a subset of peripheral T-cell lymphomas.

33 icularly frequent in all forms of gammadelta-T-cell lymphomas.

34 3 expression developed colitis and alphabeta T-cell lymphomas.

35 ate safety and efficacy in CD30(+) cutaneous T-cell lymphomas.

36 and the role EBV plays in the development of T-cell lymphomas.

37 ne mechanism for the association of EBV with T-cell lymphomas.

38 lators that are required for the survival of T-cell lymphomas.

39 T-cell lymphoma and other primary cutaneous T-cell lymphomas.

40 indicating that Dnmt1 is required to sustain T-cell lymphomas.

41 BCL6 regulation and potential links to B and T-cell lymphomas.

42 cell leukemia/lymphoma, and other peripheral T-cell lymphomas.

43 reated patients with CD30-positive cutaneous T-cell lymphomas.

44 patients with relapsed or refractory B- and T-cell lymphomas.

45 gkin lymphomas and systemic anaplastic large T-cell lymphomas.

46 cell leukaemia-lymphoma and other peripheral T-cell lymphomas.

47 ne in mice gives rise to spontaneous thymic (T-cell) lymphomas.

48 egative (ALK[-]) ALCLs, 9 angioimmunoblastic T-cell lymphomas, 11 peripheral T-cell lymphomas not oth

49 lymphomas (6.3%) of which angioimmunoblastic T-cell lymphomas (2.3%) were the most frequent, and muco

50 lymphoma and one [2%] with anaplastic large-T-cell lymphoma; 28 [43%] during phase 1 and 37 [57%] du

51 classic Hodgkin lymphomas (13%), peripheral T-cell lymphomas (6.3%) of which angioimmunoblastic T-ce

52 ngioimmunoblastic T-cell lymphoma, cutaneous T-cell lymphoma, adult T-cell leukemia/lymphoma, and oth

53 r HTLV-1 in these cases of primary cutaneous T-cell lymphoma after solid organ transplant.

54 present in 22 of 35 (67%) angioimmunoblastic T cell lymphoma (AITL) samples and in 8 of 44 (18%) PTCL

55 n 40 of 86 (47%) cases of angioimmunoblastic T-cell lymphoma (AITL) and in 22 of 58 (38%) cases of pe

56 Angioimmunoblastic T-cell lymphoma (AITL) and other lymphomas derived from

57 The genetics of angioimmunoblastic T-cell lymphoma (AITL) are very poorly understood.

58 Angioimmunoblastic T-cell lymphoma (AITL) is an uncommon subtype of mature

59 Angioimmunoblastic T-cell lymphoma (AITL) was diagnosed according to the 20

60 L-entities, including 114 angioimmunoblastic T-cell lymphoma (AITL), 31 anaplastic lymphoma kinase (A

61 However, in angioimmunoblastic T-cell lymphoma (AITL), mutations are almost exclusively

62 of IDH2R172 mutations in angioimmunoblastic T-cell lymphoma (AITL).

63 and a lower incidence of angioimmunoblastic T-cell lymphoma (AITL); Asians/Pacific Islanders had a h

64 Ls; n = 35), specifically angioimmunoblastic T-cell lymphoma (AITL; n = 13) and PTCL not otherwise sp

65 d (PTCL-NOS; n = 26) and angio-immunoblastic T-cell lymphoma (AITL; n = 46) patients treated with che

66 therwise specified [NOS], angioimmunoblastic T-cell lymphoma [AITL], and anaplastic large-cell lympho

67 emonstrated activity in refractory cutaneous T-cell lymphomas, along with acceptable toxicity.

68 on-Hodgkin, Hodgkin and nasal natural killer/T-cell lymphomas, although all three TET family genes ar

69 In T-cell lymphomas, anaplastic large-cell lymphoma is defi

70 location was found in a subset of peripheral T cell lymphomas and was shown to result in an IL-2-indu

71 umor effect of rapamycin in a mouse model of T-cell lymphoma and examine the metabolic effects in vit

72 eneration proteasome inhibitor, ixazomib, in T-cell lymphoma and Hodgkin lymphoma cells and in vivo S

73 ibited tumor growth and improved survival in T-cell lymphoma and Hodgkin lymphoma human lymphoma xeno

74 n shown to be important for cell survival in T-cell lymphoma and Hodgkin lymphoma models.

75 gulates MYC and induces potent cell death in T-cell lymphoma and Hodgkin lymphoma, and we identified

76 t is approved for the treatment of cutaneous T-cell lymphoma and is used experimentally for the deple

77 lastic cells in primary cutaneous anaplastic T-cell lymphoma and large-cell transformed cutaneous T-c

78 squamous cell cancers, as well as cutaneous T-cell lymphoma and lentigo maligna melanoma.

79 ons in DNMT3A have been recently reported in T-cell lymphoma and leukemia, implying a possible involv

80 both active and well tolerated in cutaneous T-cell lymphoma and lymphomatoid papulosis, with an over

81 (MF) is the most common subtype of cutaneous T-cell lymphoma and may rarely infiltrate the ocular str

82 f AITL, extranodal nasal-type natural killer/T-cell lymphoma and NK-cell leukemia (ENKCL), and ATLL a

83 plastic transformation in angioimmunoblastic T-cell lymphoma and other primary cutaneous T-cell lymph

84 currently being used for treating cutaneous T-cell lymphoma and under clinical trials for multiple o

85 itical for the prevention and maintenance of T-cell lymphomas and contributes to aberrant methylation

86 oncogenic gammaherpesvirus that causes acute T-cell lymphomas and leukemias in New World primates and

87 l of brentuximab vedotin for CD30+ cutaneous T-cell lymphomas and LyP from 2011 to 2013.

88 Natural killer (NK)/T-cell lymphomas and NK-cell leukemias are aggressive ma

89 logs are effective in treating leukemias and T cell lymphomas, and 6-ETI may fill this niche for the

90 acute lymphoblastic leukemia, natural killer/T-cell lymphoma, and acute myeloid leukemia, as well as

91 not otherwise specified, angioimmunoblastic T-cell lymphoma, and anaplastic lymphoma kinase (ALK)-ne

92 cell proliferation in dermatitis, cutaneous T-cell lymphoma, and graft-versus-host disease.

93 easily be mistaken for intestinal peripheral T-cell lymphoma, and lead to aggressive therapy.

94 with relapsed or refractory B-cell lymphoma, T-cell lymphoma, and multiple myeloma received the anti-

95 mor immunity in primary cutaneous anaplastic T-cell lymphoma, and provide a rationale for the pharmac

96 ng classical Hodgkin lymphoma, T-cell and NK/T-cell lymphomas, and follicular dendritic cells neoplas

97 after chemotherapy for an angioimmunoblastic-T-cell-lymphoma, and thirty-three hours after being stru

98 Cutaneous T-cell lymphomas are rare, generally incurable, and asso

99 Boxers, which develop aggressive T-cell lymphomas, are typically mutated in the PTEN-mTOR

100 n promotes genomic instability that leads to T-cell lymphomas as a consequence of altered double stra

101 s to compare in a large series of peripheral T cell lymphoma, as a model of diffuse disease, the prog

102 HTLV-1)-associated adult T-cell leukemia and T-cell lymphoma (ATL) are aggressive diseases with poor

103 roved for relapsed and refractory peripheral T-cell lymphomas based on their activity, although they

104 howing that ITK-Syk expression causes clonal T cell lymphoma by 20-27 wk of age, we investigated the

105 In a cutaneous T-cell lymphoma cell line, promoter hypermethylation was

106 ested for their activity against L5178 mouse T-cell lymphoma cells (non-MDR) and their subcell line t

107 cycle arrest in primary cutaneous anaplastic T-cell lymphoma cells in vitro and a xenograft model in

108 yndrome is a rare leukemic form of cutaneous T cell lymphoma characterized by generalized redness, sc

109 s an incurable leukemic variant of cutaneous T-cell lymphoma characterized by recurrent chromosomal a

110 Primary cutaneous anaplastic T-cell lymphoma, characterized by the CD30+ anaplastic l

111 r early-stage nasal type natural killer (NK)/T-cell lymphoma, combined radiotherapy (RT), and chemoth

112 ) >/= 2; the Prognostic Index for Peripheral T-Cell Lymphoma, comprising: age >/= 60 years, PS >/= 2,

113 -cell lymphomas constituted 83% (n = 71) and T-cell lymphomas constituted 17% (n = 15).

114 namics of active regulatory DNA in cutaneous T cell lymphoma (CTCL) by ATAC-seq.

115 In this article, we report that cutaneous T cell lymphoma (CTCL) cells and tissues ubiquitously ex

116 Cutaneous T cell lymphoma (CTCL) is a non-Hodgkin lymphoma of skin

117 a leukemic and aggressive form of cutaneous T cell lymphoma (CTCL) resulting from the malignant tran

118 hallmark of the advanced stages of cutaneous T cell lymphoma (CTCL), where it has been associated wit

119 ngle-agent treatment of refractory cutaneous T cell lymphoma (CTCL).

120 rome (SS) is a leukemic variant of cutaneous T-cell lymphoma (CTCL) and represents an ideal model for

121 Patients with cutaneous T-cell lymphoma (CTCL) are frequently colonized with Sta

122 elomerase activity (TA) in primary cutaneous T-cell lymphoma (CTCL) by using quantitative polymerase

123 HDI) resistance, we selected HuT78 cutaneous T-cell lymphoma (CTCL) cells with romidepsin in the pres

124 ry syndrome are two major forms of cutaneous T-cell lymphoma (CTCL) characterized by resistance to ap

125 cent years, a curative therapy for cutaneous T-cell lymphoma (CTCL) has not yet been developed.

126 Cutaneous T-cell lymphoma (CTCL) incidence and survival have been

127 Cutaneous T-cell lymphoma (CTCL) is a heterogeneous group of malig

128 Cutaneous T-cell lymphoma (CTCL) is a heterogeneous group of prima

129 Cutaneous T-cell lymphoma (CTCL) is an aggressive neoplasm with li

130 Cutaneous T-cell lymphoma (CTCL) is an incurable non-Hodgkin lymph

131 Cutaneous T-cell lymphoma (CTCL) is characterized by proliferation

132 ell lymphoma line, MBL2, and human cutaneous T-cell lymphoma (CTCL) lines, HH and Hut78, were used in

133 Importance: Cutaneous T-cell lymphoma (CTCL) of the hands and feet can be chal

134 ary syndrome (SS) is an aggressive cutaneous T-cell lymphoma (CTCL) of unknown etiology in which mali

135 blood involvement in patients with cutaneous T-cell lymphoma (CTCL) portend a worse clinical outcome.

136 Advanced cutaneous T-cell lymphoma (CTCL) remains an unmet medical need, wh

137 red to six healthy control and six cutaneous T-cell lymphoma (CTCL) samples from previously published

138 nes established from patients with cutaneous T-cell lymphoma (CTCL) spontaneously secrete IL-17F and

139 as FDA approval as a treatment for cutaneous T-cell lymphoma (CTCL), although treatment with 1 can el

140 NA) dysregulation is a hallmark of cutaneous T-cell lymphoma (CTCL), an often-fatal malignancy of ski

141 fungoides, the most common type of cutaneous T-cell lymphoma (CTCL), as compared to normal skin or be

142 The prognosis of advanced cutaneous T-cell lymphoma (CTCL), including Sezary syndrome and my

143 is fungoides (MF), the most common cutaneous T-cell lymphoma (CTCL), is unknown.

144 The pathogenesis of the cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF), is uncle

145 liferation, and tumor formation in cutaneous T-cell lymphoma (CTCL).

146 epression in an aggressive form of cutaneous T-cell lymphoma (CTCL).

147 own about their pathogenic role in cutaneous T-cell lymphoma (CTCL).

148 itor approved for the treatment of cutaneous T-cell lymphoma (CTCL).

149 and for monitoring progression of cutaneous T-cell lymphoma (CTCL)/SS and that FCRL3 expression corr

150 1 is FDA-approved for treatment of cutaneous T-cell lymphoma (CTCL); however, 1 can provoke side effe

151 syndrome comprise the majority of cutaneous T cell lymphomas (CTCLs), disorders notable for their cl

152 Cutaneous T-cell lymphomas (CTCLs) are a heterogeneous group of di

153 Cutaneous T-cell lymphomas (CTCLs) form a heterogeneous group of n

154 Cutaneous T-cell lymphomas (CTCLs) primarily affect skin and are c

155 Cutaneous T-cell lymphomas (CTCLs) represent a group of hematopoie

156 diseases, the malignant T cells of cutaneous T-cell lymphomas (CTCLs), such as Sezary syndrome, displ

157 een shown to be hypermethylated in cutaneous T-cell lymphomas (CTCLs), using standard bisulfite modif

158 stic large-cell lymphoma, angioimmunoblastic T-cell lymphoma, cutaneous T-cell lymphoma, adult T-cell

159 nd (CEUS) findings in enteropathy associated T-cell lymphoma (EATL) complicating CMLNS in a gluten-fr

160 Enteropathy-associated T-cell lymphoma (EATL) is a complication of celiac disea

161 Enteropathy-associated T-cell lymphoma (EATL) is a rare non-Hodgkin lymphoma fr

162 Enteropathy-associated T-cell lymphoma (EATL) is a rare subtype of peripheral T

163 led the progression of OVA257-264 expressing T-cell lymphoma EG7 (injected intradermally), the deplet

164 linical outcome of extranodal natural killer T-cell lymphoma (ENKTL) has improved substantially as a

165 In a model of cutaneous T cell lymphoma, epidermotropic CD4(+) TRM lymphoma cell

166 eous CD4+ small- to medium-sized pleomorphic T-cell lymphoma, especially in cases with a high percent

167 report about the function of TLR3 in chicken T-cell lymphoma, especially in signal pathway.

168 arcinomas, e.g. diffuse large B cell tumors, T cell lymphomas, etc.

169 In contrast, T-cell lymphomas from the predisposed breeds, boxers and

170 investigated the somatic mutations in B- and T-cell lymphomas from these breeds by exome sequencing o

171 niel), and with equal distribution of B- and T-cell lymphoma (golden retriever), respectively.

172 s immune-mediated diseases such as cutaneous T cell lymphoma, graft-versus-host disease, and organ al

173 ctory Hodgkin's lymphoma or anaplastic large-T-cell lymphoma, had biopsy-proven CD30-positive tumours

174 EBV is associated with a number of T-cell lymphomas; however, in vitro studies utilizing pr

175 The pathogenesis of hepatosplenic T-cell lymphoma (HSTL), a rare entity mostly derived fro

176 rkitt's lymphoma in humans and hepatosplenic T cell lymphomas in mice.

177 V) is an alphaherpesvirus that causes deadly T-cell lymphomas in chickens and serves as a natural sma

178 T-cell lymphomas in golden retrievers are often less agg

179 ancy in the thymus and development of CD4(+) T-cell lymphomas in the periphery.

180 We also examine T-cell lymphomas, including anaplastic large-cell lympho

181 T-cell lymphoma invasion and metastasis 1 (Tiam1) is a D

182 e the levels of Rac1-GTP and the activity of T-cell lymphoma invasion and metastasis 1 (TIAM1), a Rac

183 rolled regulator of invasion and metastasis, T-cell lymphoma invasion and metastasis 1 (TIAM1), was i

184 Tiam1 (T-cell lymphoma invasion and metastasis 1) is a guanine

185 lysis revealed that the Rac activator Tiam1 (T-cell lymphoma invasion and metastasis 1) is overexpres

186 thelial cell transforming squence 2), Tiam1 (T-cell lymphoma invasion and metastasis 1), Vav and P-Re

187 kinase activity results in the detachment of T-cell lymphoma invasion and metastasis-inducing protein

188 Thymic T cell lymphoma is the most common malignancy in p53-def

189 Cutaneous T-cell lymphoma is a heterogeneous group of lymphomas ch

190 Primary gastrointestinal (GI) T-cell lymphoma is an infrequent and aggressive disease.

191 eous CD4+ small- to medium-sized pleomorphic T-cell lymphoma is listed as a provisional entity that i

192 cell lymphoma (BIA-ALCL), a rare peripheral T-cell lymphoma, is increasing in incidence.

193 acid is already approved to treat cutaneous T-cell lymphoma, it could potentially be used as a thera

194 T-cell lymphoma (n = 9), tMF (n = 7), adult T-cell lymphoma/leukemia (n = 4), anaplastic large-cell

195 mphocytopenia and greatly increased risk for T-cell lymphomas/leukemia.

196 The murine T-cell lymphoma line, MBL2, and human cutaneous T-cell l

197 found that Notch signaling represses Ccr9 in T cell lymphoma lines in which Ccr9 transcription is ind

198 ell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoma lines in vitro and significantly inhibit

199 of origin and lymphocyte ontogeny among the T-cell lymphomas may improve our understanding of the tu

200 ts with stage IA through stage IIA cutaneous T-cell lymphoma, MF type, to evaluate treatment using to

201 ma radiation (IR)-induced replication stress T-cell lymphoma mouse model, we observed a significant i

202 stage (stage IA through stage IIA) cutaneous T-cell lymphoma, mycosis fungoides (MF) type, resulted i

203 phoma (n = 2), and extranodal natural killer/T-cell lymphoma (n = 2).

204 ded DLBCL (n = 21), MCL (n = 13), peripheral T-cell lymphoma (n = 8), transformed follicular lymphoma

205 rwise specified (n = 13), angioimmunoblastic T-cell lymphoma (n = 9), tMF (n = 7), adult T-cell lymph

206 sis (n = 9) and primary cutaneous anaplastic T-cell lymphomas (n = 2) responded; time to response was

207 5B in NK/T-cell lymphomas (n=51), gammadelta-T-cell lymphomas (n=43) and their cell lines (n=9) throu

208 tivating mutations of STAT3 and STAT5B in NK/T-cell lymphomas (n=51), gammadelta-T-cell lymphomas (n=

209 = 10; mycosis fungoides, n = 13; peripheral T-cell lymphoma, n = 5; other T-cell lymphomas, n = 5; m

210 13; peripheral T-cell lymphoma, n = 5; other T-cell lymphomas, n = 5; multiple myeloma, n = 27).

211 Natural killer/T-cell lymphoma (NKTCL) is a rare, aggressive form of no

212 Extranodal natural killer-T-cell lymphoma (NKTCL) of nasal type is a malignant dis

213 Extranodal natural killer T-cell lymphoma (NKTCL), nasal type, is a rare and aggre

214 In the current study, using natural killer/T-cell lymphoma (NKTL) as a disease model, we found that

215 rexpressed in the majority of natural killer/T-cell lymphoma (NKTL), an aggressive lymphoid malignanc

216 Nasal NK/T-cell lymphoma (NNL) is an Epstein-Barr virus (EBV)-ass

217 aplastic large-cell lymphoma, 102 peripheral T-cell lymphoma not otherwise specified, 27 angioimmunob

218 mmunoblastic T-cell lymphomas, 11 peripheral T-cell lymphomas not otherwise specified (PTCLNOS), and

219 L) and in 22 of 58 (38%) cases of peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), but

220 The most common PTCLs, peripheral T-cell lymphoma, not otherwise specified, angioimmunobla

221 Peripheral T-cell lymphoma, not otherwise specified, is a broad cat

222 Marek's disease (MD) is a T cell lymphoma of chickens induced by Marek's disease v

223 L and NSCLC, as compared with other types of T-cell lymphoma or EGFR- and K-RAS-mutated NSCLC, respec

224 Deletion of Mdm2 in T-cell lymphomas or sarcomas lacking p53 induced apoptos

225 ll responses were associated with peripheral T-cell lymphoma (OR = 2.14, 95% CI: 1.35, 3.38).

226 g pathway previously implicated in cutaneous T-cell lymphoma pathogenesis, JAK/STAT signaling, we use

227 in 252 nodal PTCL and enteropathy-associated T-cell lymphoma patients (excluding anaplastic lymphoma

228 n of mogamulizumab is warranted in cutaneous T-cell lymphoma patients.

229 Nasal NK/T-cell lymphomas present mostly with stage I/II disease.

230 ion in an elderly Asian man with undiagnosed T cell lymphoma presenting with fever of unknown origin,

231 c large cell lymphoma (ALCL) is a peripheral T-cell lymphoma presenting mostly in children and young

232 The International Peripheral T-Cell Lymphoma Project was undertaken to better underst

233 atment of immunodeficient mice bearing human T cell lymphomas promoted tumor cell apoptosis and tumor

234 c leukemia (CLL) and CD8-positive peripheral T cell lymphomas (PTCL) in EmuSRalpha-tTA;Teto-Cre;Dnmt3

235 Peripheral T-cell lymphoma (PTCL) encompasses a heterogeneous group

236 Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of aggre

237 Peripheral T-cell lymphoma (PTCL) is a rare, heterogeneous type of

238 T-cell clonality of peripheral T-cell lymphoma (PTCL) is routinely evaluated with a PCR

239 little is known about the risk in peripheral T-cell lymphoma (PTCL).

240 dotin (BV) in relapsed/refractory peripheral T-cell lymphoma (PTCL).

241 ics inflammatory bowel disease or peripheral T-cell lymphoma (PTCL).

242 is an uncommon subtype of mature peripheral T-cell lymphoma (PTCL).

243 Peripheral T-cell lymphomas (PTCL) are a group of rare malignancies

244 Peripheral T-cell lymphomas (PTCL) are aggressive diseases with poo

245 Front-line treatment of peripheral T-cell lymphomas (PTCL) involves regimens such as cyclop

246 Peripheral T cell lymphomas (PTCLs) are a heterogeneous and poorly

247 Peripheral T cell lymphomas (PTCLs) are a heterogeneous entity of n

248 Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of no

249 Peripheral T-cell lymphomas (PTCLs) are rare lymphomas with mostly

250 The peripheral T-cell lymphomas (PTCLs) encompass a heterogeneous group

251 Purpose Peripheral T-cell lymphomas (PTCLs) have aggressive clinical behavi

252 Peripheral T-cell lymphomas (PTCLs) represent a diverse group of no

253 ) represent a large proportion of peripheral T-cell lymphomas (PTCLs) with poorly understood pathogen

254 eported for CD30(+) nonanaplastic peripheral T-cell lymphomas (PTCLs) with promising efficacy.

255 emain elusive for the most common peripheral T-cell lymphomas (PTCLs).

256 ial diagnosis among the commonest peripheral T-cell lymphomas (PTCLs; ie, PTCL not otherwise specifie

257 t analysis included patients with peripheral T-cell lymphomas (PTCLs; n = 35), specifically angioimmu

258 ukaemia-lymphoma, four with other peripheral T-cell lymphomas) receiving lenalidomide, dose-limiting

259 tically accelerated incidence of both B- and T-cell lymphomas relative to Emu-D1T286A or ATM-/- contr

260 are limited, and the genetic basis of these T cell lymphomas remains incompletely characterized.

261 lymphoma, mycosis fungoides, and peripheral T-cell lymphoma, respectively.

262 randomly selected BCL6-positive human B- and T-cell lymphomas, revealed concurrent expression of BCL6

263 eity in chromosome instability-driven murine T-cell lymphoma samples, indicating ongoing chromosome i

264 utely transforming retrovirus AKT8 in rodent T-cell lymphoma/signal transducer and activator of trans

265 utely transforming retrovirus AKT8 in rodent T-cell lymphoma signaling.

266 One hundred six patients with peripheral T cell lymphoma, staged with PET/CT, were enrolled from

267 frequent than CDKN2A (12%) in all cutaneous T-cell lymphoma stages using quantitative reverse transc

268 The specific role of MTAP in cutaneous T-cell lymphoma subgroups, mycosis fungoides (MF) and Se

269 immunosuppression, whereas the hepatosplenic T-cell lymphoma subtype and cases with involvement of bo

270 the pathological and clinical aspects of the T-cell lymphoma subtypes as well as NK-cell lymphomas an

271 -cell leukaemia-lymphoma or other peripheral T-cell lymphoma subtypes, and at least one previous anti

272 n the NCI1312 phase 2 study of romidepsin in T-cell lymphoma suggested perturbation of the MAPK pathw

273 in the absence of gene amplification, e.g., T cell lymphoma (TCL).

274 vitro and in vivo activity of everolimus in T-cell lymphoma (TCL) and pave the way for future combin

275 tudy investigated mTOR pathway activation in T-cell lymphoma (TCL) cell lines and assessed antitumor

276 NHL), chronic lymphocytic leukemia (CLL), or T-cell lymphoma (TCL) were treated with 25 or 75 mg duve

277 otein, the dominant form of ALK expressed in T cell lymphomas (TCLs), closely resembles cell activati

278 tivated growth-related signaling pathways in T-cell lymphomas (TCLs).

279 cell lymphoma (ALCL) is a distinct entity of T-cell lymphoma that can be divided into 2 subtypes base

280 astic large cell lymphoma (ALCL) is a mature T-cell lymphoma that can present as a systemic or primar

281 -cell leukemia/lymphoma and 44 extranodal NK/T-cell lymphoma that were further separated into NK-cell

282 cell lymphoma (ALCL), a specific subtype of T-cell lymphoma, the Rho family GTPases Cdc42 and Rac1 a

283 ients with Hodgkin's lymphoma and peripheral T-cell lymphoma, treatment with bendamustine alone only

284 onstrate that rapamycin suppresses growth of T-cell lymphoma tumors and leads to a reduction in aerob

285 IB is expressed heterogeneously among B- and T-cell lymphoma types.

286 t otherwise specified, 27 angioimmunoblastic T-cell lymphoma) undergoing autologous HCT (autoHCT; n =

287 es (MF) is the most common primary cutaneous T-cell lymphoma variant and is closely related to a rare

288 In 2 of 3 organ recipients, a cutaneous T-cell lymphoma was diagnosed 2 and 3 years after infect

289 ith a history of stage IV angioimmunoblastic T-cell lymphoma was diagnosed with osteomyelitis of the

290 The risk for T-cell lymphoma was increased (HR, 3.51 [CI, 0.75 to 16.

291 Therefore, its role in the T-cell lymphomas was examined.

292 f younger patients developing hepato-splenic T-cell lymphoma while taking thiopurines with and withou

293 psed or refractory systemic anaplastic large-T-cell lymphoma who previously received at least one che

294 eous CD4+ small- to medium-sized pleomorphic T-cell lymphoma with an admixture of numerous CD20+ B ce

295 cision confirmed relapsed angioimmunoblastic T-cell lymphoma with atypical lymphocytes expressing CD3

296 phoma (EATL) is a rare subtype of peripheral T-cell lymphomas with a poor prognosis.

297 ALK was first identified in a subset of T-cell lymphomas with anaplastic large cell lymphoma (AL

298 AITL now resides under the umbrella of nodal T-cell lymphomas with follicular T helper phenotype.

299 hromatin accessibility profiles of cutaneous T cell lymphoma, with dynamic assessments of response an

300 ecause of an initial diagnosis of peripheral T-cell lymphoma, with little or no response, whereas the